Dr. Robert E. Dunn, MD
Cardiac Electrophysiology (Clinical Cardiac Electrophysiology Physician)
At a glance
- In the NPI registry since
- 2018
The NPI date is when this clinician registered for a National Provider Identifier, the billing number used on health claims. It is not a license, graduation or board-certification date. What an NPI is
Education and training
- 2018Registered with an NPI (national billing number; not a license date)
Medicare’s Care Compare data doesn’t list this clinician’s medical school. Undergraduate school, residency, fellowship, licensing exams and board certification aren’t in public federal data. Board certification can be confirmed with the certifying board (ABMS member boards for MDs, AOA boards for DOs).
Specialties and state licenses
-
Clinical Cardiac Electrophysiology Physician primary
NC license 2026-02410 -
Cardiovascular Disease Physician
NC license 2026-02410 -
Internal Medicine Physician
NC license 2026-02410 - Student in an Organized Health Care Education/Training Program
As reported to the NPI registry. To confirm a license is current, check the state medical board.
Payments from drug and device companies
In 2025, 1 companies reported 9 payments worth $14,373 in total to this clinician.
| Boston Scientific Corporation | $14,373 |
|---|
| Grant | $12,000 |
|---|---|
| Food and Beverage | $1,564 |
| Travel and Lodging | $809 |
What the payments were for
| Company | What it was for | Amount |
|---|---|---|
| Boston Scientific Corporation Oct 16, 2025 | Grant EMBLEM MRI S-ICD · EMBLEM_CRM | $12,000 |
| Boston Scientific Corporation Dec 5, 2025 | Travel and Lodging FARAPULSE · FARAPULSE_EP · travel to New York City, NY · in-kind | $330 |
| Boston Scientific Corporation Dec 6, 2025 | Travel and Lodging FARAPULSE · FARAPULSE_EP · travel to New York City, NY · in-kind | $330 |
| Boston Scientific Corporation Dec 6, 2025 | Travel and Lodging FARAPULSE · FARAPULSE_EP · travel to New York City, NY · in-kind | $148 |
Each payment as the company reported it, with the products it named. Meals are counted in the totals above but not listed one by one.
From CMS Open Payments. A payment is not evidence of wrongdoing; many are for consulting, teaching or meals. Clinicians can review and dispute their records with CMS.
Industry-funded research
Named as a principal investigator on 22 industry-funded studies in 2025, from 2 companies. The companies reported $32,552 in research payments for these studies, mostly to the institutions running them.
- A Study of Tirzepatide (LY3298176) Compared With Dulaglutide on Major Cardiovascular Events in Participants With Type 2 Diabetes
Eli Lilly and Company · Completed · NCT04255433 - A Study of Tirzepatide (LY3298176) on the Reduction on Morbidity and Mortality in Adults With Obesity
Eli Lilly and Company · Active, not recruiting · NCT05556512 - A Study to Investigate the Effect of Lepodisiran on the Reduction of Major Adverse Cardiovascular Events in Adults With Elevated Lipoprotein(a) - ACCLAIM-Lp(a)
Eli Lilly and Company · Active, not recruiting · NCT06292013 - A Study of Daily Oral Orforglipron (LY3502970) Compared With Insulin Glargine in Participants With Type 2 Diabetes and Obesity or Overweight at Increased Cardiovascular Risk
Eli Lilly and Company · Completed · NCT05803421 - A Study of Baricitinib in Participants With Rheumatoid Arthritis
Eli Lilly and Company · Completed · NCT04086745 - A Study of Baricitinib (LY3009104) in Participants With Rheumatoid Arthritis
Eli Lilly and Company · Completed · NCT03915964 - A Study of Orforglipron in Adult Participants With Obesity or Overweight and Type 2 Diabetes
Eli Lilly and Company · Completed · NCT05872620 - A Study of Orforglipron (LY3502970) in Adult Participants With Obesity or Overweight With Weight-Related Comorbidities
Eli Lilly and Company · Active, not recruiting · NCT05869903 - Effect of Retatrutide Compared With Semaglutide in Adult Participants With Type 2 Diabetes and Inadequate Glycemic Control With Metformin With or Without SGLT2 Inhibitor (TRANSCEND-T2D-2)
Eli Lilly and Company · Active, not recruiting · NCT06260722 - A Study of Orforglipron (LY3502970) Compared With Dapagliflozin in Adult Participants With Type 2 Diabetes and Inadequate Glycemic Control With Metformin
Eli Lilly and Company · Completed · NCT06192108
From CMS Open Payments research payments, where companies name up to five principal investigators per payment. Research payments usually go to hospitals, universities and research sites, not to the investigator personally. A payment is not evidence of wrongdoing.